MRI Contrast Agents for Liver Cancer
(HERO Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
To predict response of HCC to TACE using dynamic oxygen-enhanced (dOE)-MRI for assessment of the level of tumor hypoxia before and after treatment.
Are You a Good Fit for This Trial?
This trial is for people with liver cancer (HCC) who are scheduled to receive a treatment called TACE. Participants should be able to safely undergo MRI scans and use contrast agents. Those with conditions that make MRI unsafe or who can't have contrast agents cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pre-Treatment Assessment
Oxygen-enhanced MRI is performed to assess hypoxic levels of hepatocellular carcinoma before treatment
Treatment
Participants undergo transarterial chemoembolization (TACE) as per clinical standard of care
Post-Treatment Assessment
Oxygen-enhanced MRI is performed to assess hypoxic levels of hepatocellular carcinoma after treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Trial Overview
The study uses a special type of MRI scan, called dynamic oxygen-enhanced MRI, before and after TACE treatment to see if it can predict how well the liver tumor responds by measuring oxygen levels in the tumor.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
a diagnostic test (MRI)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Université de Montréal
Lead Sponsor
Laboratory ISTCT UMR6030 CNRS of Caen (France)
Collaborator
Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.